Topic: fragile X syndrome
Instead of seeking the underlying cause of a group of symptoms, scientists started with a mutation and then tracked down people who have it.
Boehringer is paying €25 million upfront and committing to up to €600 million more to land an option on Autifony’s schizophrenia drug.
Zynerba’s stock doubled on news of the route to redemption, despite the study’s lack of a control arm leaving reason to question the drug's effect.
A new target for the treatment of MeCP2 duplication syndrome could be useful in treating autism and other neurological conditions.
Researchers led by McGill University are investigating whether the diabetes drug metformin might effectively treat fragile X syndrome, a cause of autism.
Ovid Therapeutics has hit the bottom of the range in its IPO, resulting in it grossing $75 million.